Researchers Published Meta-Analysis of MDMA Therapy
A new living systematic review offers updated evidence on MDMA-assisted therapy for PTSD.
Updated on Oct. 11, 2026 in Substance Abuse
Live Poll
Would you consider experimental therapies as a valid alternative to traditional psychiatric medications?
Researchers published a living systematic review and meta-analysis examining the use of MDMA-assisted therapy for PTSD. They also launched an interactive online dashboard to provide continuous updates to the evidence base as new data becomes available.
Why it matters
The study was initiated to synthesize evidence on MDMA efficacy due to limitations in current PTSD treatment options and trial designs. Current FDA-approved treatments for PTSD remain limited to paroxetine and sertraline.
PTSD impacts 6% of the general population and 17.1% of military service members, costing $23.2 billion annually in care and lost productivity. The MDMA-assisted therapy protocol involves dosing sessions that typically last 8 to 10 hours.
The players
SYPRES
This research platform was developed by the study team to provide transparent access to MDMA-assisted therapy data and analysis code.
The details
The research team created the SYPRES website to host raw data, effect sizes, and analysis code for public and professional review. This systematic approach aims to provide a clearer picture of treatment outcomes compared to existing trauma-focused cognitive behavioral therapies.
Timeline
The living systematic review was published on October 11, 2026.
Health Landscape
This study challenges the existing reliance on the FDA-approved treatments for PTSD, which currently consist only of paroxetine and sertraline. By introducing MDMA-assisted therapy as a potential alternative, the research signals a significant shift in the medical trajectory for managing trauma-related disorders.
Patients and providers can now access the SYPRES database to evaluate the latest findings on MDMA-assisted therapy efficacy and protocol requirements. This resource helps clarify the rigorous 8 to 10-hour dosing sessions involved in the therapeutic process compared to standard treatments.
The takeaway
This living systematic review provides a centralized resource for clinicians and patients to track the development of new PTSD treatment protocols. Stakeholders can utilize these updated datasets to better understand how emerging therapies compare to traditional medical standards.
What happens next
The research team plans to update the living systematic review and the associated evidence database at least annually.
Further reading
For more information on current treatment trends, visit the Substance Abuse section.
More information
Access the comprehensive SYPRES research data and results for detailed study analysis.
Source note: This article includes information reported by Nature.
Live Poll
Would you consider experimental therapies as a valid alternative to traditional psychiatric medications?
